[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2017141536A - Замещенные производные индол-5-ола и их терапевтические применения - Google Patents

Замещенные производные индол-5-ола и их терапевтические применения Download PDF

Info

Publication number
RU2017141536A
RU2017141536A RU2017141536A RU2017141536A RU2017141536A RU 2017141536 A RU2017141536 A RU 2017141536A RU 2017141536 A RU2017141536 A RU 2017141536A RU 2017141536 A RU2017141536 A RU 2017141536A RU 2017141536 A RU2017141536 A RU 2017141536A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
compound
composition
paclitaxel
formula
Prior art date
Application number
RU2017141536A
Other languages
English (en)
Inventor
Чуньлинь ТАО
Original Assignee
Нэнтбайосайенс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нэнтбайосайенс, Инк. filed Critical Нэнтбайосайенс, Инк.
Publication of RU2017141536A publication Critical patent/RU2017141536A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)

Claims (38)

1. Соединение формулы:
Figure 00000001
2. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.1 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
3. Композиция по п.2, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
4. Соединение формулы:
Figure 00000002
5. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.4 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
6. Композиция по п.5, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
7. Соединение формулы:
Figure 00000003
8. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.7 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
9. Композиция по п.8, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
10. Соединение формулы:
Figure 00000004
11. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.10 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
12. Композиция по п.11, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
13. Соединение формулы:
Figure 00000005
14. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.13 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
15. Композиция по п.14, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
16. Соединение формулы:
Figure 00000006
17. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.16 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
18. Композиция по п.17, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
19. Соединение формулы:
Figure 00000007
20. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.19 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
21. Композиция по п.20, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
22. Соединение формулы:
Figure 00000008
23. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.22 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
24. Композиция по п.23, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
25. Соединение формулы:
Figure 00000009
26. Фармацевтическая композиция, обладающая противоопухолевой активностью, содержащая, в эффективном количестве, соединение по п.25 или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
27. Композиция по п.26, дополнительно содержащая дополнительный цитотоксический терапевтический агент, выбранный из паклитаксела.
28. Применение соединения по любому из пп.1, 4, 7, 10, 16, 19, 22 или 25 для лечения ракового заболевания.
29. Применение соединения по любому из пп.1, 4, 7, 10, 16, 19, 22 или 25 для получения лекарственного средства для лечения ракового заболевания.
RU2017141536A 2013-03-15 2014-03-17 Замещенные производные индол-5-ола и их терапевтические применения RU2017141536A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361852309P 2013-03-15 2013-03-15
US61/852,309 2013-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015143657A Division RU2015143657A (ru) 2013-03-15 2014-03-17 Замещенные производные индол-5-ола и их терапевтические применения

Publications (1)

Publication Number Publication Date
RU2017141536A true RU2017141536A (ru) 2019-02-13

Family

ID=51537983

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017141536A RU2017141536A (ru) 2013-03-15 2014-03-17 Замещенные производные индол-5-ола и их терапевтические применения
RU2015143657A RU2015143657A (ru) 2013-03-15 2014-03-17 Замещенные производные индол-5-ола и их терапевтические применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015143657A RU2015143657A (ru) 2013-03-15 2014-03-17 Замещенные производные индол-5-ола и их терапевтические применения

Country Status (11)

Country Link
US (2) US9550760B2 (ru)
EP (1) EP2968332A4 (ru)
JP (2) JP2016514703A (ru)
KR (1) KR101871561B1 (ru)
CN (2) CN107954991A (ru)
AU (1) AU2014233069A1 (ru)
BR (1) BR112015022307A2 (ru)
CA (1) CA2906185A1 (ru)
IL (1) IL241359A0 (ru)
RU (2) RU2017141536A (ru)
WO (1) WO2014145403A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718915C2 (ru) * 2015-02-27 2020-04-15 Нэнтбайосайенс, Инк. Производные пиримидина в качестве ингибиторов киназ и их терапевтические применения

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010109A2 (pt) 2012-11-05 2017-07-11 Nant Holdings Ip Llc derivados de indol-5-ol substituídos e suas aplicações terapêuticas
CN107954991A (zh) * 2013-03-15 2018-04-24 南特生物科学公司 取代的吲哚-5-酚衍生物和它们的治疗应用
MA45973A (fr) 2015-08-31 2019-06-26 Pharmacyclics Llc Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA46783A (fr) 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de type thérapie cellulaire t et inhibiteur de btk
CA3098497A1 (en) 2018-05-03 2019-11-07 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
SI1553097T1 (sl) 1999-02-10 2010-12-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji angiogeneze in intermediati za to
US6703420B1 (en) * 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
JP5049447B2 (ja) 2000-08-14 2012-10-17 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
US20070117785A1 (en) 2000-08-14 2007-05-24 Butler Christopher R Substituted pyrazoles and methods of treatment with substituted pyrazoles
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
US20050101587A9 (en) 2000-08-14 2005-05-12 Butler Christopher R. Method for treating allergies using substituted pyrazoles
RU2278863C2 (ru) 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
UA81420C2 (en) * 2002-06-20 2008-01-10 Vertex Pharma Process for the preparation of substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
AU2003261807B9 (en) 2002-08-30 2007-02-15 Eisai R & D Management Co., Ltd. Azaarene derivatives
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
US7713960B2 (en) * 2005-07-22 2010-05-11 University Of South Florida Inhibition of the Raf/Mek/P-Erk pathway for treating cancer
EP1934200A1 (en) 2005-09-15 2008-06-25 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2007056163A2 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8013153B2 (en) * 2006-03-23 2011-09-06 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
KR101424847B1 (ko) 2007-04-16 2016-07-08 허치슨 메디파르마 엔터프라이즈 리미티드 피리미딘 유도체
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
CA2730930C (en) * 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
BRPI1010887A2 (pt) * 2009-06-08 2016-12-27 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas.
BR112015010109A2 (pt) * 2012-11-05 2017-07-11 Nant Holdings Ip Llc derivados de indol-5-ol substituídos e suas aplicações terapêuticas
US9056262B2 (en) * 2012-11-08 2015-06-16 Mks Instruments, Inc. Pressure-less ozonated Di-water (DIO3) recirculation reclaim system
CN107954991A (zh) * 2013-03-15 2018-04-24 南特生物科学公司 取代的吲哚-5-酚衍生物和它们的治疗应用
KR20160084363A (ko) 2013-06-28 2016-07-13 난토믹스, 엘엘씨 진단 검사의 확인을 위한 경로 분석

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718915C2 (ru) * 2015-02-27 2020-04-15 Нэнтбайосайенс, Инк. Производные пиримидина в качестве ингибиторов киназ и их терапевтические применения

Also Published As

Publication number Publication date
WO2014145403A1 (en) 2014-09-18
US10245261B2 (en) 2019-04-02
AU2014233069A1 (en) 2015-09-24
EP2968332A4 (en) 2016-08-03
EP2968332A1 (en) 2016-01-20
US20160016945A1 (en) 2016-01-21
KR20150140688A (ko) 2015-12-16
RU2015143657A (ru) 2017-04-27
BR112015022307A2 (pt) 2017-07-18
JP2018087200A (ja) 2018-06-07
JP2016514703A (ja) 2016-05-23
US20170189400A1 (en) 2017-07-06
CA2906185A1 (en) 2014-09-18
CN105377261A (zh) 2016-03-02
KR101871561B1 (ko) 2018-06-27
US9550760B2 (en) 2017-01-24
CN107954991A (zh) 2018-04-24
IL241359A0 (en) 2015-11-30
CN105377261B (zh) 2017-12-15

Similar Documents

Publication Publication Date Title
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
JP2015078230A5 (ru)
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
WO2016080810A3 (ko) 바이구아나이드 화합물 및 이의 용도
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
JP2015502926A5 (ru)
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201890532A1 (ru) Новые аннелированные бензамиды
PH12014502743A1 (en) Carbamate/urea derivatives
JP2015516419A5 (ru)
PH12018501709A1 (en) Naphthridinedione derivatives
PH12015501945A1 (en) Formulations of organic compounds
JP2014148552A5 (ru)
JP2016515550A5 (ru)
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents
CR20150092A (es) Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo
RU2012115543A (ru) Противоопухолевое средство

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20201130